The biopharmaceutical company posted a consolidated net profit of ₹141 crore for the June quarter, compared with ₹31.4 crore in the year-ago period. Revenue from operations rose 10% year-on-year to ₹4,336 crore from ₹3,942 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) increased 10.6% to ₹847.2 crore from ₹766.1 crore a year earlier, while EBITDA margin improved marginally to 19.54% from 19.43%. Gross EBITDA stood at ₹902 crore with a margin of 21%, supported by improved profitability in the Biopharma business.
Executive Chairperson Kiran Mazumdar-Shaw said the company entered FY27 with a focus on translating strategic investments into sustainable growth, adding that an improving policy environment for biosimilars and expanded manufacturing capabilities in the US reinforce its long-term growth prospects.
The company’s Biopharma business continued to be the key growth driver during the quarter, with revenue rising 17% year-on-year to ₹3,615 crore. Biosimilars revenue grew 16% to ₹2,855 crore, while generics revenue increased 21% to ₹760 crore, aided by momentum from recent biosimilar and generic product launches across key markets.
However, services revenue declined 16% to ₹736 crore due to continued challenges in the business.
Biocon also reported a 23% year-on-year decline in interest costs to ₹213 crore after measures to strengthen its balance sheet. Net research and development expenses rose 17% to ₹240 crore during the quarter.
Chief Executive Officer and Managing Director Shreehas Tambe said Biocon launched Bosaya and Aukelso (biosimilar Denosumab), Yesafili (biosimilar Aflibercept) and generic Liraglutide in the US during the quarter, while also securing European Medicines Agency approval for its insulin fill-finish facility in Malaysia.He added that the company expects growth momentum to accelerate through the year, leading to a stronger second-half performance.
During the quarter, Biocon commercialised Yesafili in the US as an interchangeable biosimilar to Aflibercept, launched Evfraxy for bone health across multiple European markets and expanded its presence in emerging markets through new product approvals and partnerships.
Shares of the company ended 0.76% higher at ₹425.20 ahead of the results announcement on Wednesday. The stock has advanced about 10% so far in 2026 and more than 14% over the last 12 months.
Also read: Godrej Agrovet Q1 profit falls 14% as margin pressure offsets revenue growth
